60,000 Shares in Regulus Therapeutics Inc. (NASDAQ:RGLS) Purchased by Peak6 LLC

Peak6 LLC acquired a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $95,000.

Other institutional investors also recently bought and sold shares of the company. State Street Corp raised its stake in shares of Regulus Therapeutics by 3.5% during the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at about $46,000. Barclays PLC grew its position in shares of Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 52,059 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Regulus Therapeutics by 20.5% during the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 19,900 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGLS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, March 14th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $28.00 price target on shares of Regulus Therapeutics in a research note on Monday, March 17th. Finally, Wells Fargo & Company raised shares of Regulus Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $3.00 to $6.00 in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Regulus Therapeutics Trading Down 2.4 %

NASDAQ RGLS opened at $2.01 on Tuesday. The business’s 50-day moving average price is $1.51 and its 200 day moving average price is $1.47. Regulus Therapeutics Inc. has a twelve month low of $0.83 and a twelve month high of $2.90. The company has a market capitalization of $133.15 million, a PE ratio of -1.88 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). During the same quarter in the previous year, the business earned ($0.40) EPS. Equities analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Insider Activity

In other news, CEO Joseph P. Hagan bought 50,000 shares of Regulus Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the acquisition, the chief executive officer now owns 260,808 shares of the company’s stock, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.35% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.